Oncopeptides AB (publ)
ONPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $447,330 | $546,160 | $728,164 | $1,299,764 |
| - Cash | $178,536 | $173,407 | $344,515 | $362,187 |
| + Debt | $121,894 | $126,156 | $9,542 | $14,193 |
| Enterprise Value | $390,688 | $498,909 | $393,191 | $951,770 |
| Revenue | $31,648 | $35,220 | $8,355 | $118,295 |
| % Growth | -10.1% | 321.5% | -92.9% | – |
| Gross Profit | $28,985 | $36,299 | $8,349 | $65,174 |
| % Margin | 91.6% | 103.1% | 99.9% | 55.1% |
| EBITDA | -$283,498 | -$231,622 | -$319,636 | -$1,405,430 |
| % Margin | -895.8% | -657.6% | -3,825.7% | -1,188.1% |
| Net Income | -$284,607 | -$249,111 | -$337,951 | -$1,430,317 |
| % Margin | -899.3% | -707.3% | -4,044.9% | -1,209.1% |
| EPS Diluted | -1.87 | -2.76 | -4.11 | -19 |
| % Growth | 32.2% | 32.8% | 78.4% | – |
| Operating Cash Flow | -$260,570 | -$279,493 | -$420,509 | -$1,516,391 |
| Capital Expenditures | $0 | -$116 | -$2,507 | -$339 |
| Free Cash Flow | -$260,570 | -$279,609 | -$423,016 | -$1,516,730 |